

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
07 July 2022 (07.07.2022)



(10) International Publication Number
WO 2022/147448 A1

(51) International Patent Classification:

A61K 31/42 (2006.01) *A61K 31/41* (2006.01)
A61K 31/422 (2006.01) *C07D 261/02* (2006.01)
A61K 31/4245 (2006.01) *A61K 31/445* (2006.01)

(21) International Application Number:

PCT/US2021/073153

(22) International Filing Date:

29 December 2021 (29.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/132,363 30 December 2020 (30.12.2020) US

(71) Applicant: **TERNS PHARMACEUTICALS, INC.**

[US/US]; 1065 E. Hillsdale Blvd., Suite 100, Foster City,
CA 94404 (US).

(72) Inventors: **XU, Yingzi**; 1065 E. Hillsdale Blvd., Suite 100,

Foster City, CA 94404 (US). **KLUCHER, Kevin**; 1065 E.
Hillsdale Blvd., Suite 100, Foster City, CA 94404 (US).

ROMERO, F., Anthony; 1065 E. Hillsdale Blvd., Suite
100, Foster City, CA 94404 (US).

(74) Agent: **SNYDER, Seth** et al.; Morrison & Foerster LLP,

755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: COMPOUNDS AND METHODS FOR MODULATING FXR

(57) Abstract: Disclosed herein are compounds that can be used as Farnesoid X Receptor (FXR) agonists, compositions containing these compounds and methods of use thereof.



WO 2022/147448 A1